The prostate cancer therapeutics market 2013 2023

©noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision-gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur-chase and single copy is for personal use only.

The Prostate Cancer Therapeutics Market 2013-2023

www.visiongain.com

Contents

1.1 Overview of Prostate Cancer Therapeutics Market

1.2 Overview of Findings

1.3 Chapter Outline

1.4 Research and Analysis Method

1.5 Glossary of Terms Relating to Prostate Cancer Therapeutics Market

2.1 What is Cancer?

2.2 Phenotypic Characteristics of Cancer Cells

2.2.1 Uncontrollable Growth

2.2.2 Loss of Apoptosis Pathways

2.2.3 Lack Differentiation

2.2.4 Increased Angiogenesis

2.2.5 Potential for Metastasis

2.2.6 Genetic Instability

2.3 What Causes Cancer?

2.4 Worldwide Prevalence of Cancer: A Global Picture

2.5 What is Prostate Cancer?

2.6 Worldwide Prevalence of Prostate Cancer: Rapid Global Growth

2.7 Risk Factors for Prostate Cancer

2.8 How is Prostate Cancer Diagnosed?

2.8.1 PSA Testing

2.8.2 Digital Rectal Examination Testing

1. Executive Summary

2. Introduction

www.visiongain.com

Contents 2.8.3 Newly Approved Tests May Improve Diagnosis

2.9 Treatment Sequence for Prostate Cancer

2.9.1 Localised Prostate Cancer: Surgery/Radiation is Most Preferred

2.9.1.1 Brachytherapy

2.9.1.2 Radical Prostatectomy

2.9.1.3 External Beam Radiation Therapy

2.9.1.4 Cryotherapy

2.9.1.5 High-Intensity Focussed Ultrasound (HIFU)

2.9.2 Androgen Deprivation Therapy

2.9.3 Non-Metastatic CRPC: Ketoconazole and Anti-Androgens

2.9.4 Metastatic CRPC: Provenge Loosing its Dominance

2.9.5 First Line Chemotherapy: Docetaxel is a Standard Treatment

2.9.6 Post Docetaxel Therapy: Four FDA Approved Drugs

2.9.7 Second Line Chemotherapy: Jevtana Approved in 2010

3.1 The Global Prostate Cancer Therapeutics Market, 2012

3.2 The Global Prostate Cancer Therapeutics Market Forecast, 2012-2017

3.3 The Global Prostate Cancer Therapeutics Market Forecast, 2017-2023

3.4 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2013-2023

4.1 The Prostate Cancer Drugs Market is Highly Competitive

4.2 The Prostate Cancer Drugs Market, 2012

4.3 The Prostate Cancer Drugs Market Forecast, 2012-2017

3. The Prostate Cancer Therapeutics Market 2013-2023

4. The Prostate Cancer Drugs Market 2013-2023

www.visiongain.com

Contents 4.4 The Prostate Cancer Drugs Market Forecast, 2017-2023

4.5 Leading Prostate Cancer Drugs: Market Prospects, 2012-2023

4.5.1 Zytiga (Johnson &Johnson/Janssen)

4.5.1.1 Zytiga Sales, 2012

4.5.1.2 Zytiga Sales Forecast, 2012-2023

4.5.2 Lupron (AbbVie)

4.5.2.1 Lupron Sales, 2012

4.5.2.2 Lupron Sales Forecast, 2012-2023

4.5.3 Zoladex (AstraZeneca)

4.5.3.1 Zoladex Sales, 2012

4.5.3.2 Zoladex Sales Forecast, 2012-2023

4.5.4 Casodex (AstraZeneca)

4.5.4.1 Casodex Sales, 2012

4.5.4.2 Casodex Sales Forecast, 2012-2023

4.5.5 Taxotere (Sanofi)

4.5.5.1 Taxotere Sales, 2012

4.5.5.2 Taxotere Sales Forecast, 2012-2023

4.5.6 Provenge (Dendreon Corporation)

4.5.6.1 Provenge Sales, 2012

4.5.6.2 Provenge Sales Forecast, 2012-2023

4.5.7 Jevtana (Sanofi)

4.5.7.1 Jevtana Sales, 2012

4.5.7.2 Jevtana Sales Forecast, 2012-2023

4.5.8 Xtandi (Medivation/Astellas Pharma)

4.5.8.1 Xtandi Sales, 2012

www.visiongain.com

Contents 4.5.8.2 Xtandi Sales Forecasts, 2012-2023

4.6 Late Stage Clinical Trial Failures, 2013

4.6.1 Aflibercept (Zaltrap, Regeneron/Sanofi)

4.6.2 Dasatinib (Sprycel, Bristol Myers Squibb)

4.6.3 Lenalidomide (Revlimid, Celgene)

4.6.4 TAK-700 (Orteronel, Takeda)

4.7 Prostate Cancer Drugs Pipeline, 2013

4.7.1 Yervoy (Bristol Myers Squibb)

4.7.2 Cabozantinib (Exelixis)

4.7.3 Tasquinimod (Active Biotech AB/Ipsen)

4.7.4 Prostvac (Bavarian Nordic)

4.7.5 Custirsen (OncoGenex Pharmaceuticals)

4.7.6 MDV-3100 (Medivation/Astellas Pharma)

4.7.7 ProstAtak (Advantagene)

4.7.8 DCVax-Prostate (NorthWest Biotherapeutics)

4.7.9 GVAX Prostate (Aduro Biotech)

4.7.10 GDC-0980 (Roche)

4.7.11 PSMA ADC (Progenics Pharmaceuticals)

4.7.12 EMD-525797 (EMD Sereno)

4.7.13 Galeterone (Tokai Pharmaceuticals)

4.7.14 OGX-427 (OncoGenex Pharmaceuticals)

4.7.15 ARN-509 (Johnson & Johnson)

4.7.16 MGAH22 (MacroGenics)

4.7.17 RG7450 (Roche)

4.7.18 ASG-5ME (Agensys/Seattle Genetics)

www.visiongain.com

Contents 4.7.19 BAY2010112 (Bayer Pharmaceuticals)

4.7.20 GDC-0068 (Roche)

4.8 Leading Companies in the Prostate Cancer Drugs Market, 2013

4.8.1 Johnson & Johnson (J&J)

4.8.1.1 Sales and Performance Analysis, 2012

4.8.1.2 Pharmaceutical Segment Sales Analysis, 2012

4.8.1.3 Pharmaceutical Segment R&D Performance Analysis, 2012

4.8.1.4 Recent M&A Activity

4.8.1.4.1 Acquisition of Aragon Pharmaceuticals

4.8.2 AstraZeneca


4.8.2.2 R&D Performance Analysis, 2012

4.8.3 Sanofi


4.8.3.2 Oncology Sales and Performance Analysis, 2012


4.8.3.4 Recent M&A Activity

5.1 The Prostate Cancer Devices Market, 2012

5.2 Prostate Cancer Devices Market Forecast, 2012-2017

5.3 Prostate Cancer Devices Market Forecast, 2017-2023

5.4 Brachytherapy Market 2012-2023: Driven By Physician Adoption

5.5 Radical Prostatectomy Market 2012-2023: Higher Patient Preference

5.5.1 Intuitive Surgical’s da Vinci Surgical System will Drive Market Growth

5. The Prostate Cancer Devices Market 2013-2023

www.visiongain.com

Contents 5.6 External Beam Radiation Therapy Market 2012-2023

5.7 Cryotherapy Market 2012-2023: Fastest Growing Market

5.8 HIFU Market 2012-2023: Driven by Demand for Non-Invasive Surgery

5.9 Leading Companies in the Prostate Cancer Devices Market, 2012

5.9.1 Varian Medical Systems


5.9.1.2 Oncology Systems Sales Analysis, 2012


5.9.1.4 Key Oncology Products, 2013

5.9.1.5 Varian and Siemens Partnership: Shaping the Future of Cancer Care

5.9.2 Elekta


5.9.2.2 Elekta and Philips Establish Research Consortium

6.1 Regional Breakdown of the Prostate Cancer Therapeutics Market, 2012

6.2 The Prostate Cancer Therapeutics Market: Regional Forecast 2012-2023

6.3 The US Market 2012-2023: Largest National Market

6.4 The EU5 Market 2012-2023

6.4.1 Germany and France 2012-2023: Two Largest EU Markets

6.4.2 The UK Market 2012-2023: Budgetary Constraints

6.4.3 The Spanish Market 2012-2023: Facing Cost Containment Measures

6.4.4 The Italian Market 2012-2023: Slow Growth Owing to Economic Crisis

6.5 The Japanese Market 2012-2023: Driven by Aging Population

6.6 The BRIC Nations 2012-2023: Strong Potential for Growth

6. The Leading National Markets 2013-2023

www.visiongain.com

Contents 6.6.1 The Chinese Market 2012-2023: Highest Revenue Generator Among BRIC Nations

6.6.2 The Indian Market 2012-2023: Lucrative Opportunity for Growth

6.6.3 The Russian Market 2012-2023: Rising Incidence of Cancer

6.6.4 The Brazilian Market 2012-2023: BRIC’s Smallest Market

7.1 SWOT Analysis, 2013-2023

7.2 Strengths

7.2.1 Prostate Cancer is a High Profile Disease

7.2.2 Rapidly Expanding Aging Population

7.2.3 Strong R&D Pipeline

7.2.4 Use of Off-Label Drugs are Common

7.3 Weaknesses

7.3.1 Prostate Cancer Drugs are Expensive

7.3.2 R&D Failures in Late Stage Development

7.3.3 Impact of Economic Downturn on Healthcare Spending

7.4 Opportunities

7.4.1 Rising Incidence of Cancer

7.4.2 Emerging National Markets will Drive Growth

7.4.3 Stem Cells Offer Promise

7.4.4 Advances in Diagnostic Technologies: CTC as a Biomarker

7.5 Threats

7.5.1 Concerns about Efficacy and Toxicity of Drugs

7. Qualitative Analysis of the Prostate Cancer Therapeutics Market

2013-2023

www.visiongain.com

Contents 7.5.2 Who will pay for the High Cost of Drugs and Devices?

7.5.3 Governments Cut Down Healthcare Spending

7.5.4 Increase in Generic Competition

7.6 Porter’s Five Force Analysis

7.6.1 Rivalry Among Competitors

7.6.2 Threat of New Entrants

7.6.3 Power of Suppliers

7.6.4 Power of Buyers

7.6.5 Threat of Substitutes

8.1 Interview with Dr. Deepak Batura, Consultant Urological Surgeon

8.1.1 Views on Early-Stage Prostate Cancer Treatment

8.1.2 Advantages of Using Robots for Prostatectomy

8.1.3 Potential of HIFU to Replace Conventional Therapies

8.1.4 Does Eating Right Reduce Prostate Cancer Risk?

8.1.5 Outlook for Future

9.1 The Prostate Cancer Therapeutics Market, 2012-2023

9.2 The US Will Remain the Largest National Market during 2012-2023

9.3 Concluding Remarks

8. Expert Opinion

9. Conclusions

www.visiongain.com

Contents

Table 2.1 PSA Testing: Benefits and Limitations, 2013

Table 2.2 New Prostate Cancer Diagnostic Tests in Market, 2013

Table 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($bn) and Market Shares

(%) by Segment, 2012

Table 3.2 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%),

CAGR (%), 2012-2017

Table 3.3 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%),

CAGR (%), 2017-2023

Table 3.4 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2013-2023

Table 4.1 The Prostate Cancer Drugs Market: Revenue ($bn) and Market Shares (%) by Leading

Drugs, 2012

Table 4.2 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%),

2012-2017

Table 4.3 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%),

2017- 2023

Table 4.4 Zytiga: Revenue Forecast ($bn), AGR (%), CAGR (%), 2012-2023

Table 4.5 Lupron: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023

Table 4.6 Zoladex: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023

Table 4.7 Casodex: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023

Table 4.8 Taxotere : Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023

Table 4.9 Provenge: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023

Table 4.10 Jevtana: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023

Table 4.11 Xtandi: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023

Table 4.12 Negative Phase III Trials in which Targeted Drug was Added to Docetaxel, 2013

List of Tables

www.visiongain.com

Contents Table 4.13 Key Drugs in Phase III Clinical Trials, 2013

Table 4.14 Key Drugs in Phase II Clinical Trials, 2013

Table 4.15 Key Drugs in Phase I Clinical Trials, 2013

Table 4.16 Johnson & Johnson: Revenue ($bn) and Revenue Shares (%) by Segment, 2012

Table 4.17 Johnson & Johnson: Pharmaceutical Revenue ($bn) and Revenue Shares (%) by

Segment, 2012

Table 4.18 Johnson & Johnson: Oncology Drugs Historical Sales ($m), 2010-2012

Table 4.19 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D

Expenses as Percentage of Segment Revenue (%), 2010-2012

Table 4.20 AstraZeneca: Revenue ($bn) and Revenue Shares (%) by Segment, 2012

Table 4.21 AstraZeneca: Anti-Cancer Drugs Revenue ($bn), Change in Revenue (%) and

Revenue Shares (%), 2011-2012

Table 4.22 Selected Drugs from AstraZeneca Oncology Pipeline, 2012

Table 4.23 Sanofi: Net Sales ($bn) and Net Sales Shares (%) by Segment, 2012

Table 4.24 Sanofi: Net Sales ($bn) and Net Sales Shares (%) by Region, 2012

Table 4.25 Sanofi: Oncology Sales ($bn) by Product, 2012

Table 4.26 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue

(%), 2010-2012

Table 5.1 The Prostate Cancer Devices Market: Revenue ($m) and Market Shares (%) by

Segment, 2012

Table 5.2 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%), CAGR (%) by

Segment, 2012-2017

Table 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%), CAGR (%) by

Segment, 2017-2023

Table 5.4 Brachytherapy Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023

www.visiongain.com

Contents Table 5.5 Radical Prostatectomy Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-

2023

Table 5.6 External Beam Radiation Therapy Market: Revenue Forecast ($m), AGR (%) CAGR

(%), 2012-2023

Table 5.7 Cryotherapy Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023

Table 5.8 HIFU Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023

Table 5.9 Varian Medical Systems: Revenue ($bn) and Revenue Shares (%) by Segment, 2012

Table 5.10 Varian Medical Systems: Oncology Systems Revenue ($bn) and Revenue Shares (%)

by Segment, 2012

Table 5.11 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as

Percentage of Revenue (%), 2010-2012

Table 5.12 Elekta: Net Sales ($bn) and Net Sales Shares (%) by Region, 2012

Table 6.1 The Prostate Cancer Therapeutics Market: Revenue ($bn) and Market Shares (%) by

Region, 2012

Table 6.2 The Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR

(%) by Region, 2012-2017

Table 6.3 The Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR

(%) by Region, 2017-2023

Table 6.4 The US Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023

Table 6.5 The EU5 Prostate Cancer Therapeutics National Markets: Revenue ($bn) and Market

Shares (%) by Country, 2012

Table 6.6 The EU5 Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%),

CAGR (%) by Region, 2012-2017

Table 6.7 The EU5 Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%),

CAGR (%) by Region, 2017-2023

Table 6.8 The German and French Markets: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-

2023

www.visiongain.com

Contents Table 6.9 The UK Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023

Table 6.10 The Spanish Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023

Table 6.11 The Italian Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023

Table 6.12 The Japanese Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023

Table 6.13 The BRIC Prostate Cancer Therapeutics Market: Revenue ($m) and Global Market

Shares (%) by Country, 2012

Table 6.14 The BRIC Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%),

CAGR (%) by Country, 2012-2017

Table 6.15 The BRIC Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%),

CAGR (%) by Country, 2017-2023

Table 6.16 The Chinese Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023

Table 6.17 The Indian Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023

Table 6.18 The Russian Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023

Table 6.19 The Brazilian Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023

Table 7.1 SWOT Analysis of the Prostate Cancer Therapeutics Market, 2013-2023

Table 9.1 Segments in the Prostate Cancer Therapeutics Market: Sales ($bn) in 2012, 2017,

2019 and 2023

Table 9.2 The Prostate Cancer Therapeutics Market by Leading Regional Markets: Sales ($bn) in

2012, 2017, 2019 and 2023

Table 9.3 Market Shares (%) of the Leading Regional Prostate Cancer Therapeutics Markets in

2012, 2017, 2019 and 2023

www.visiongain.com

Contents

Figure 2.1 Treatment Sequence for Prostate Cancer, 2013

Figure 3.1 The Global Prostate Cancer Therapeutics Market: Revenues ($bn) by Segment, 2012

Figure 3.2 The Global Prostate Cancer Therapeutics Market: Market Shares (%) by Segment,

2012

Figure 3.3 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2017

Figure 3.4 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2017-2023

Figure 4.1 The Prostate Cancer Drugs Market: Revenue ($bn) by Leading Drugs, 2012

Figure 4.2 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drugs, 2012

Figure 4.3 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), 2012-2017

Figure 4.4 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), 2017-2023

Figure 4.5 Zytiga: Revenue Forecast ($bn), 2012-2023

Figure 4.6 Lupron: Revenue Forecast ($bn), 2012-2023

Figure 4.7 Zoladex: Revenue Forecast ($bn), 2012-2023

Figure 4.8 Casodex: Revenue Forecast ($bn), 2012-2023

Figure 4.9 Taxotere: Revenue Forecast ($bn), 2012-2023

Figure 4.10 Provenge: Revenue Forecast ($bn), 2012-2023

Figure 4.11 Jevtana: Revenue Forecast ($bn), 2012-2023

Figure 4.12 Xtandi: Revenue Forecast ($bn), 2012-2023

Figure 4.13 Johnson & Johnson: Revenue Shares (%) by Segment, 2012

Figure 4.14 Johnson & Johnson: Historical Revenue ($bn), Net Income ($bn) and Profit Margin

(%), 2007-2012

Figure 4.15 Johnson & Johnson: Pharmaceutical Revenue ($bn) by Segment, 2012

Figure 4.16 Johnson & Johnson: Pharmaceutical Revenue Shares (%) by Segment, 2012

List of Figures

www.visiongain.com

Contents Figure 4.17 Johnson & Johnson: Pharmaceutical Segment Historical Revenue ($bn) by Region,

2010-2012

Figure 4.18 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D

Expenses as Percentage of Segment Revenue (%), 2010-2012

Figure 4.19 AstraZeneca: Revenue ($bn) by Segment, 2012

Figure 4.20 AstraZeneca: Revenue Shares (%) by Segment, 2012

Figure 4.21 AstraZeneca: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of

Revenue (%), 2008-2012

Figure 4.22 Sanofi: Historical Revenue Performance ($bn), 2008-2012

Figure 4.23 Sanofi: Net Sales ($bn) by Segment, 2012

Figure 4.24 Sanofi: Net Sales Shares (%) by Segment, 2012

Figure 4.25 Sanofi: Net Sales Shares (%) by Region, 2012

Figure 4.26 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue

(%), 2010-2012

Figure 5.1 The Prostate Cancer Devices Market: Revenue ($m) by Segment, 2012

Figure 5.2 The Prostate Cancer Devices Market: Market Shares (%) by Segment, 2012

Figure 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m), 2012-2023

Figure 5.4 The Brachytherapy Market Forecast: Revenue ($m), 2012-2023

Figure 5.5 The Radical Prostatectomy Market Forecast: Revenue ($m), 2012-2023

Figure 5.6 The External Beam Radiation Therapy Market Forecast: Revenue ($m), 2012-2023

Figure 5.7 The Cryotherapy Market Forecast: Revenue ($m), 2012-2023

Figure 5.8 The HIFU Market Forecast: Revenue ($m), 2012-2023

Figure 5.9 Varian Medical Systems: Revenue ($bn) by Segment, 2012

Figure 5.10 Varian Medical Systems: Revenue Shares (%) by Segment, 2012

Figure 5.11 Varian Medical Systems: Historical Revenue ($bn), 2008-2012

www.visiongain.com

Contents Figure 5.12 Varian Medical Systems: Revenue Shares (%) by Region, 2012

Figure 5.13 Varian Medical Systems: Oncology Systems Revenue ($bn) by Segment, 2012

Figure 5.14 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Segment, 2012

Figure 5.15 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Region, 2012

Figure 5.16 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as

Percentage of Revenue (%), 2010-2012

Figure 5.17 Elekta: Historical Net Sales ($bn), 2008-2012

Figure 5.18 Elekta: Net Sales Shares (%) by Region, 2012

Figure 6.1 The Prostate Cancer Therapeutics Market: Revenue ($bn) by Region, 2012

Figure 6.2 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2012

Figure 6.3 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023

Figure 6.4 The EU5 Prostate Cancer Therapeutics National Markets: Revenue ($bn) by Country,

2012

Figure 6.5 The EU5 Prostate Cancer Therapeutics National Markets: Market Shares (%) by

Country, 2012

Figure 6.6 The EU5 Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023

Figure 6.7 The German and French Prostate Cancer Therapeutics Market Forecast: Revenue

($bn), 2012-2023

Figure 6.8 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023

Figure 6.9 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-

2023

Figure 6.10 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-

2023

Figure 6.11 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-

2023

Figure 6.12 The BRIC Prostate Cancer Therapeutics Market: Revenue ($m), by Country, 2012

www.visiongain.com

Contents Figure 6.13 The BRIC Prostate Cancer Therapeutics Market: Global Market Shares (%) by

Country, 2012

Figure 6.14 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012-

2023

Figure 6.15 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012-2023

Figure 6.16 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012-

2023

Figure 6.17 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012-

2023

Figure 7.1 Porter’s Five Force Analysis of the Prostate Cancer Therapeutics Market, 2013-2023

Figure 9.1 Prostate Cancer Therapeutics Market: Sales ($bn) in 2012, 2017, 2019 and 2023

Figure 9.2 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2023

www.visiongain.com

Contents

AbbVie

Accord Healthcare

Actavis, Inc.

Active Biotech AB

Aduro Biotech

Advanced Medical Isotope Corporation

Advantagene, Inc.

Agensys

American Cancer Society

Amgen

Antoni Van Leeuwenhoek Hospital

Aragon Pharmaceuticals

Astellas Pharma

AstraZeneca

Bavarian Nordic

Bayer HealthCare

Beckman Coulter, Inc.

Bellicum Pharmaceuticals, Inc.

BioSante Pharmaceuticals

Bostwick Laboratories

Bristol Myers Squibb

BTG plc

C.R. Bard, Inc.

Organisations Mentioned in This Report

www.visiongain.com

Contents Calypso

Cancer Research UK

Cedars-Sinai Medical Centre

Celgene Corporation

Committee for Medicare and Medicaid Services

Computer Motion

Cougar Biotechnology

Dendreon Corporation

Dosch Pharmaceuticals Pvt Ltd

Ealing Hospital NHS Trust

EDAP TMS

Elekta

EMD Serono

European Association of Urology

European Medicines Agency (EMA)

European Partnership Action Against Cancer (EPAAC)

Exelixis

Food and Drug Administration (FDA)

Genentech (Roche)

Genfar Laboratories

GenomeDX Biosciences

Genomic Health, Inc.

Genzyme

GLOBOCAN

www.visiongain.com

Contents Hologic, Inc.

Hospira Inc

Intuitive Surgical

Ipsen

Iris International

Italian National Health Service

Johnson & Johnson

Levine Cancer Institute

MacroGenics

MDxHealth

Medical College of Wisconsin

Medivation

Metabolon, Inc.

Metamark Genetics

Micromet (Amgen)

Mitomics, Inc.

Mylan Pharmaceuticals, Inc.

Myriad Genetics

National Cancer Institute (NCI)

National Epidemiological Centre

National Health Service (NHS)

National Institute of Clinical Excellence (NICE)

Newport Laboratories

NorthWest Biotherapeutics

www.visiongain.com

Contents Nucletron

OncoGenex Pharmaceuticals

Oncura, Inc.

Opko Health, Inc.

Philips

Pluromed, Inc.

Princess Margaret Cancer Center

Progenics Pharmaceuticals, Inc.

Radon Ltd

Regeneron Pharmaceuticals, Inc.

Roche

Sandoz

Sanofi

Seattle Genetics

Siemens

SonaCare Medical

Sun Pharmaceuticals Ltd

Sunnybrook Health Sciences Centre

Synthon Pharmaceuticals, Inc.

Takeda Pharmaceutical Co Ltd

Teva

The Clinical Cancer Center at Froedtert

The Netherlands Cancer Institute

The University of Texas MS Anderson Centre

www.visiongain.com

Contents Tokai Pharmaceuticals, Inc.

United Nations (UN)

University Medical Centre Utrecht

University of California

University of York

Varian Medical Systems

World Health Organisation

YCR Cancer Research

Zydus Pharmaceuticals

www.visiongain.com


4.5.3 Zoladex (AstraZeneca) Zoladex is a luteinising hormone releasing hormone (LHRH) agonist that acts on the pituitary gland

in the brain to control the secretion of oestrogen and testosterone. It is classified as a hormone

therapy. As some breast cancers are caused by oestrogen and some prostrate cancers by

testosterone, modulating the amounts of the hormone in a patient can cause their tumours to

shrink. Zoladex is approved to treat prostate cancers and breast cancers. The drug is injected

subcutaneously every four weeks or as a longer acting preparation every 12 weeks.

4.5.3.1 Zoladex Sales, 2012 In 2012, Zoladex generated total revenue of $1.1bn, a decrease of 7.6% from 2011 sales figures of

$1.2bn. As mentioned earlier, Zoladex is indicated for both prostate and breast cancer. However,

the company does not provide an individual breakdown for the two indications. According to

visiongain estimates, Zoladex (for prostate cancer indication) generated revenue worth $0.6bn and

represented 12.7% of the total prostate cancer drugs market. Zoladex faces competition from

similar products like Eligard (Sanofi) and Lupron (AbbVie). Zoladex’s patent will expire in 2021 in

both the US and Europe. After that, visiongain expects Zoladex to come under significant pressure

from a generic version.

Figure 4.6 Lupron: Revenue Forecast ($bn), 2012-2023

0.7

0.7

0.7

0.6

0.6

0.6

0.5

0.4 0.4

0.3

0.3

0.3

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

Rev

enue

($bn

)

Year

Source: Visiongain 2013

www.visiongain.com


4.7.14 OGX-427 (OncoGenex Pharmaceuticals) OGX-427 is a second generation once weekly intravenous experimental drug, which inhibits the

production of heat shock protein 27 (Hsp27). Hsp27 is a cell survival protein found at elevated

levels in many human cancers. There are currently two phase II investigational programs (Pacific

and OGX-427-PR01) for OGX-427 which aims to demonstrate the drug’s ability to inhibit Hsp27 in

prostate cancer patients.

4.7.15 ARN-509 (Johnson & Johnson) ARN-509 is being developed on the success of enzalutamide. Like enzalutamide, this drug works

through competitive androgen receptor inhibition that is purely antagonistic. It has also been shown

to reduce efficiency of nuclear translocation of the androgen receptor and impairs androgen

receptor binding to androgen-response element of the DNA. The preclinical evidence for ARN-509

as a promising therapeutic agent has led to the opening of the phase II trial evaluating the

efficiency of the drug with various CRPC states. The results are expected to be generated by 2018.

As a result, it will not be a major competitor to Xtandi in the next 7-8 years.

Table 4.15 shows key drugs in phase I development in the prostate cancer drugs market. These

drugs are profiled below.

Table 4.15 Key Drugs in Phase I Clinical Trials, 2013

Drug Company Type

MGAH22 MacrogenicsFc-optimised monoclonal antibody (mAb) that targets HER2

RG7450 Roche Humanised mAb targeting STEAP1

ASG-5ME Agensys/Seattle GeneticsASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen

BAY2010112 Bayer Pharmaceuticals

Novel BiTE antibody that is bispecific for prostate-specific membrane antigen (PSMA) and the CD3 epsilon subunit of the T cell receptor complex

GDC-0068 Roche Inhibitor of the serine/threonine protein kinase, AktBPX-101 Bellicum Pharmaceuticals Novel drug activated dendritic cell vaccine

Source: Visiongain 2013

www.visiongain.com


4.8.1.3 Pharmaceutical Segment R&D Performance Analysis, 2012 The total R&D spending in the pharmaceutical segment in 2012 was $5.4bn, which represented

21.2% of the segment revenue. The expenditure in R&D has increased over the years, with a jump

of $1.0bn from 2010 to 2012. However, the R&D expenses as percentage of net sales has

remained almost consistent as the net sales have increased over the years. Table 4.19 and Figure

4.18 show the historical R&D expenses ($m) and R&D expenses as percentage of segment

revenue (%) from 2010-2012.

Table 4.19 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Segment Revenue (%), 2010-2012

Year R&D Expenses ($bn)Percentage of Segment Revenue (%)

2010 4.4 19.82011 5.1 21.12012 5.4 21.2

Figure 4.18 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Segment Revenue (%), 2010-2012

19

19.5

20

20.5

21

21.5

0.0

1.0

2.0

3.0

4.0

5.0

6.0

2010 2011 2012

Perc

enta

ge o

f Seg

men

t Rev

enue

(%)

R&

D E

xpen

ses

($bn

)

Year

Source: J&J2013; Visiongain 2013

Source: J&J2013; Visiongain 2013

The prostate cancer therapeutics market 2013 2023

Business

Transcript of The prostate cancer therapeutics market 2013 2023